Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):535-46. doi: 10.1016/j.bpg.2011.10.013.


Aminosalicylates are the most common drugs for the primary treatment of inflammatory bowel disease. Various pro-drugs and formulations were developed in order to improve pharmacological profiles, optimize bioavailability and to gain highest efficacy in the treatment of ulcerative colitis (UC) and Crohn's disease. In vitro studies have greatly contributed to the understanding of the molecular actions in vivo and clinical studies have proven aminosalicylates to be effective and safe. This review summarizes the current knowledge on the molecular, pharmacological and clinical properties of aminosalicylates with respect to chemoprevention for UC-associated colorectal cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aminosalicylic Acids / pharmacokinetics
  • Aminosalicylic Acids / therapeutic use*
  • Animals
  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / therapeutic use*
  • Anticarcinogenic Agents / pharmacokinetics
  • Anticarcinogenic Agents / therapeutic use*
  • Chemoprevention
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / pathology
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / prevention & control*
  • Crohn Disease / drug therapy*
  • Gastrointestinal Agents / pharmacokinetics
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Precancerous Conditions / drug therapy*
  • Precancerous Conditions / pathology
  • Treatment Outcome


  • Aminosalicylic Acids
  • Anti-Inflammatory Agents
  • Anticarcinogenic Agents
  • Gastrointestinal Agents